SEC Filing Summary

This filing details transactions related to Day One Biopharmaceuticals, Inc. (DAWN) on April 23, 2026, following a merger agreement. Natalie C. Holles, a director, was involved in several transactions. All outstanding unvested stock options and restricted stock units became fully vested at the effective time of the merger. These options and RSUs were then canceled and converted into the right to receive cash equal to the merger consideration, with a per-share price of $21.50. Specifically, 57,310 shares of common stock were disposed of. Additionally, various stock options totaling 200,335 shares and 15,000 Restricted Stock Units (RSUs) were also disposed of. All these transactions resulted in a post-transaction share count of zero for these holdings.